Peter R Carroll

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2915323/publications.pdf

Version: 2024-02-01

28 2,757 papers citations

17 28
h-index g-index

29 29 all docs citations

29 times ranked 3643 citing authors

#	Article	IF	CITATIONS
1	Active surveillance in intermediate-risk prostate cancer with PSA 10–20 ng/mL: pathological outcome analysis of a population-level database. Prostate Cancer and Prostatic Diseases, 2022, 25, 690-693.	2.0	8
2	Multiple Tissue Biomarkers Independently and Additively Predict Prostate Cancer Pathology Outcomes. European Urology, 2021, 79, 141-149.	0.9	4
3	Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion Sequencing. JCO Precision Oncology, 2021, 5, 710-725.	1.5	6
4	Natural history of an immediately detectable PSA following radical prostatectomy in a contemporary cohort. Prostate, 2021, 81, 1009-1017.	1.2	2
5	Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death. Journal of Clinical Oncology, 2021, 39, 2284-2293.	0.8	54
6	Individual Patient Data Meta-analysis of Discrimination of the Four Kallikrein Panel Associated With the Inclusion of Prostate Volume. Urology, 2021, , .	0.5	1
7	Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. JCO Precision Oncology, 2020, 4, 1228-1238.	1.5	2
8	A machine learning approach to optimizing cell-free DNA sequencing panels: with an application to prostate cancer. BMC Cancer, 2020, 20, 820.	1.1	14
9	The New Surveillance, Epidemiology, and End Results Prostate with Watchful Waiting Database: Opportunities and Limitations. European Urology, 2020, 78, 335-344.	0.9	28
10	Regional Variation in Active Surveillance for Low-Risk Prostate Cancer in the US. JAMA Network Open, 2020, 3, e2031349.	2.8	41
11	Natural language processing systems for pathology parsing in limited data environments with uncertainty estimation. JAMIA Open, 2020, 3, 431-438.	1.0	10
12	Risk Factors for Biopsy Reclassification over Time in Men on Active Surveillance for Early Stage Prostate Cancer. Journal of Urology, 2020, 204, 1216-1221.	0.2	9
13	Feasibility and Acceptability of a Remotely Delivered, Web-Based Behavioral Intervention for Men With Prostate Cancer: Four-Arm Randomized Controlled Pilot Trial. Journal of Medical Internet Research, 2020, 22, e19238.	2.1	25
14	Trends and Predictors of Adjuvant Therapy for Adverse Features Following Radical Prostatectomy: An Analysis From Cancer of the Prostate Strategic Urologic Research Endeavor. Urology, 2019, 131, 157-165.	0.5	7
15	The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement. European Urology, 2019, 76, 268-272.	0.9	28
16	Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. Journal of Clinical Oncology, 2018, 36, 581-590.	0.8	162
17	The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer. European Urology, 2018, 74, 444-452.	0.9	55
18	Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer. European Urology Oncology, 2018, 1, 386-394.	2.6	32

#	Article	IF	CITATIONS
19	Effect of Increasing Levels of Web-Based Behavioral Support on Changes in Physical Activity, Diet, and Symptoms in Men With Prostate Cancer: Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2018, 7, e11257.	0.5	9
20	Transâ€< scp>Pacific variation in outcomes for men treated with primary androgenâ€deprivation therapy (<scp>ADT</scp>) for prostate cancer. BJU International, 2016, 117, 102-109.	1.3	57
21	Overdetection of Recurrence after Radical Prostatectomy: Estimates Based on Patient and Tumor Characteristics. Clinical Cancer Research, 2014, 20, 5302-5310.	3.2	19
22	A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling. European Urology, 2014, 66, 550-560.	0.9	553
23	Vegetable and fruit intake after diagnosis and risk of prostate cancer progression. International Journal of Cancer, 2012, 131, 201-210.	2.3	91
24	Physical Activity after Diagnosis and Risk of Prostate Cancer Progression: Data from the Cancer of the Prostate Strategic Urologic Research Endeavor. Cancer Research, 2011, 71, 3889-3895.	0.4	241
25	The CAPRAâ€ S score. Cancer, 2011, 117, 5039-5046.	2.0	359
26	Intakes of meat, fish, poultry, and eggs and risk of prostate cancer progression. American Journal of Clinical Nutrition, 2010, 91, 712-721.	2.2	61
27	Risk Assessment for Prostate Cancer Metastasis and Mortality at the Time of Diagnosis. Journal of the National Cancer Institute, 2009, 101, 878-887.	3.0	287
28	THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CANCER OF THE PROSTATE RISK ASSESSMENT SCORE: A STRAIGHTFORWARD AND RELIABLE PREOPERATIVE PREDICTOR OF DISEASE RECURRENCE AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2005, 173, 1938-1942.	0.2	592